Skip to content

US · LUNG · MEDICAL - DEVICES

Pulmonx Corporation (LUNG) intrinsic value and stock valuation

$2.57as of 2026-11-21 · Mkt cap 83.63M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pulmonx Corporation DCF and intrinsic value

InvestorsCraft values LUNG with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from LUNG’s statements →

Pulmonx Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Redwood City, CA 94063 pulmonx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$90.5M+22.6% 5y CAGRd
20182025
Net income
-$-54M
20182025
Free cash flow
-$-32.9M
20182025
Total equity
$54.1M-24.9% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$90.5M$83.8M$68.7M$53.7M$48.4M
Operating income-$-53.66M-$-57.7M-$-61.94M-$-58.64M-$-47.3M
Net income-$-54M-$-56.39M-$-60.84M-$-58.92M-$-48.66M
EPSd-$-1.33M-$-1.44M-$-1.6M-$-1.59M-$-1.35M
Operating cash flow-$-32.45M-$-31.54M-$-37.61M-$-45.14M-$-41.43M
Capital expenditure-$-450K-$-1.45M-$-810K-$-1.32M-$-3.67M
Free cash flow-$-32.9M-$-32.98M-$-38.42M-$-46.45M-$-45.1M
Total assets$129.3M$162.9M$177.8M$193.7M$235.2M
Total debt$56.4M$56.5M$41.4M$24.4M$26.5M
Net debt-$-13.64M-$-14.43M-$-42.12M-$-77.33M-$-122.02M
Total equity$54.1M$85.8M$118.3M$154M$193.2M
Cash and short-term investments$70M$101.5M$117.1M$141.1M$180M
Income statement
20252024202320222021
Revenue$90.5M$83.8M$68.7M$53.7M$48.4M
Cost of revenue$23.4M$21.8M$17.9M$13.8M$12.8M
Gross profit$67.1M$62M$50.8M$39.9M$35.6M
Research and development expenses$19.5M$17.6M$18.1M$15.4M$13.1M
Selling, general and administrative expenses$101.3M$102.1M$94.6M$83.1M$69.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$120.8M$119.7M$112.7M$98.5M$82.9M
Cost and expenses$144.2M$141.5M$130.6M$112.3M$95.7M
Interest income$2.65M$5.06M$5.57M$1.53M$400K
Interest expense$3.15M$3.51M$3.23M$1.07M$830K
Depreciation and amortization$1.05M$1.59M$1.95M$1.51M$870K
Ebitda-$-49.17M-$-50.79M-$-55.09M-$-55.99M-$-46.62M
Operating income-$-53.66M-$-57.7M-$-61.94M-$-58.64M-$-47.3M
Total other income/expenses, net$290K$1.81M$1.66M$70K-$-1.01M
Income before tax-$-53.38M-$-55.89M-$-60.27M-$-58.57M-$-48.32M
Income tax expense$630K$500K$570K$350K$340K
Net income-$-54M-$-56.39M-$-60.84M-$-58.92M-$-48.66M
Weighted average shares outstanding$40.7M$39.1M$38M$37.1M$36.1M
Weighted average diluted shares outstanding$40.7M$39.1M$38M$37.1M$36.1M
Balance sheet
20252024202320222021
Cash and short-term investments$70M$101.5M$117.1M$141.1M$180M
Net receivables$12.1M$13.8M$13M$9.28M$6.92M
Inventory$15.9M$16.9M$16.7M$14.6M$16.3M
Total current assets$101.7M$136.3M$150.4M$169M$208M
Property, plant and equipment, net$20.3M$21.5M$7.43M$10.5M$12.9M
Goodwill and intangible assets$3.03M$2.33M$2.36M$2.49M$2.61M
Long-term investments$0.00$0.00$14.4M$5.92M$10.9M
Total non-current assets$27.6M$26.6M$27.4M$24.7M$27.2M
Total assets$129.3M$162.9M$177.8M$193.7M$235.2M
Accounts payable$3.9M$3.83M$1.5M$1.76M$1.58M
Short-term debt$1.32M$3.95M$5.23M$3.32M$2.29M
Deferred revenue$20K$140K$100K$120K$160K
Total current liabilities$20.1M$24.4M$23.2M$18.5M$17.6M
Long-term debt$55.1M$52.5M$36.2M$21.1M$24.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$55.1M$52.6M$36.3M$21.2M$24.4M
Capital lease obligations$18.1M$19.3M$4.18M$7.08M$9.04M
Total liabilities$75.2M$77M$59.5M$39.7M$41.9M
Common stock$40K$40K$40K$40K$40K
Retained earnings-$-521.56M-$-467.56M-$-411.16M-$-350.32M-$-291.39M
Accumulated other comprehensive income (loss)$2.36M$2.11M$2.64M$1.57M$1.71M
Total equity$54.1M$85.8M$118.3M$154M$193.2M
Total investments$0.00$30.6M$48M$45.3M$42.5M
Total debt$56.4M$56.5M$41.4M$24.4M$26.5M
Net debt-$-13.64M-$-14.43M-$-42.12M-$-77.33M-$-122.02M
Cash flow statement
20252024202320222021
Net income-$-54M-$-56.39M-$-60.84M-$-58.92M-$-48.66M
Depreciation and amortization$1.15M$1.49M$1.55M$4M$3.16M
Stock-based compensation$0.00$23M$22.1M$0.00$0.00
Change in working capital-$-1.93M-$-1.7M-$-2.56M-$-7.06M-$-7.84M
Accounts receivable$1.07M-$-1.31M-$-3.1M-$-2.19M-$-2.43M
Inventory-$-770K-$-230K$920K-$-3.64M-$-6.46M
Accounts payable$270K$2.28M-$-340K$250K$90K
Net cash provided by operating activities-$-32.45M-$-31.54M-$-37.61M-$-45.14M-$-41.43M
Investments in property, plant and equipment-$-450K-$-1.45M-$-810K-$-1.32M-$-3.67M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$30.5M$17.5M-$-2.01M-$-4.22M-$-46.26M
Common stock issued$1M$0.00$0.00$2.59M$4.52M
Common stock repurchased$0.00$0.00$0.00-$-30K-$-30K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$900K$1.36M$21.4M$2.47M$4.5M
Net change in cash-$-1.15M-$-12.62M-$-18.18M-$-46.74M-$-83.08M
Cash at end of period$70M$71.2M$83.8M$102M$148.7M
Operating cash flow-$-32.45M-$-31.54M-$-37.61M-$-45.14M-$-41.43M
Capital expenditure-$-450K-$-1.45M-$-810K-$-1.32M-$-3.67M
Free cash flow-$-32.9M-$-32.98M-$-38.42M-$-46.45M-$-45.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pulmonx Corporation

        Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

        CEO
        Glendon E. French
        Employees
        296
        Beta
        0.31

        Explore

        Frequently asked questions

        What is the intrinsic value of Pulmonx Corporation (LUNG)?

        Pulmonx Corporation (LUNG) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LUNG undervalued?

        LUNG trades at a price of $2.57 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.